Premium
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
Author(s) -
Holme I.,
Fayyad R.,
Faergeman O.,
Kastelein J. J. P.,
Olsson A. G.,
Tikkanen M. J.,
Larsen M. L.,
Lindahl C.,
Holdaas H.,
Pedersen T. R.
Publication year - 2010
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.2009.02176.x
Subject(s) - medicine , kidney disease , ideal (ethics) , disease , atherosclerotic cardiovascular disease , cardiology , intensive care medicine , philosophy , epistemology
. Holme I, Fayyad R, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Holdaas H, Pedersen TR, On behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (Centre of Preventive Medicine, Oslo, Norway; Århus University Hospital, Århus, Denmark; Academic Hospital Amsterdam, Amsterdam, The Netherlands; University Hospital, Linköping, Sweden; Helsinki University Central Hospital, Helsinki, Finland; Oslo University Hospital, Rikshospitalet, Oslo, Norway; Pfizer Sweden, Sollentuna, Sweden; and Pfizer Inc., New York, NY, USA). Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: Results from the IDEAL trial. J Intern Med 2010; 267 :567–575. Objectives. In Incremental Decrease in Endpoints through Aggressive Lipid‐lowering (IDEAL), we compared cardiovascular outcomes in patients with and without chronic kidney disease (CKD) (estimated glomerular filtration rate <60 mL min −1 1.73 m −2 ) and analysed relationships between lipoprotein components (LC) and major coronary events (MCE) and other cardiovascular (CV) events. Design. Exploratory analysis of CV endpoints in a randomized trial comparing high dose of atorvastatin to usual dose of simvastatin on MCE. Settings. Patients with CKD were compared with the non‐CKD patients. Cox regression models were used to study the relationships between on‐treatment levels of LC and incident MCE. Findings. Chronic kidney disease was strongly associated with cardiovascular end‐points including total mortality. In patients with CKD, a significant benefit of high dose atorvastatin treatment was found for any CV events, stroke and peripheral artery disease, but not for MCE. However, all cardiovascular end‐points except stroke and CV mortality were reduced in the non‐CKD group. Differential changes in LC or relationships to LC could not explain the different treatment outcomes in MCE in the two groups. Interpretation. Chronic kidney disease was a powerful risk factor for all cardiovascular end‐points. The reason why the significant reductions achieved by high‐dose statin treatment in most CV end‐points in the non‐CKD group were only in part matched by similar reductions in the CKD patients is not apparent. This difference did not result from differential changes in or relations to LC, but limited power may have increased the possibility of chance findings.